Skip to main content

Arvinas, Inc.

corporate_fare Company Profile

Arvinas, Inc.

ARVN·NASDAQ·Life Sciences·CIK 0001655759

Arvinas, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for debilitating and life-threatening diseases. The company utilizes its PROteolysis TArgeting Chimera, or PROTAC, protein degradation platform to develop a new class of therapeutics. These therapeutics are designed to use the body's natural protein disposal system to selectively degrade and remove disease-causing proteins. Arvinas has developed and optimized its proprietary PROTAC Discovery Engine to identify PROTAC therapeutics for diseases caused by abnormal proteins or aberrant protein expression. The company believes its targeted protein degradation approach is a novel therapeutic modality that may offer advantages over existing therapies and target a broad range of proteins, including those previously considered undruggable. Over the past five years, seven programs developed using Arvinas's PROTAC protein degradation platform have advanced to clinical trials in oncology and neurology indications, following preclinical studies demonstrating potent and selective protein degradation. The U.S. Food and Drug Administration, or FDA, has accepted the company's New Drug Application, or NDA, for vepdegestrant, its most advanced product candidate from the platform. Vepdegestrant is intended for the treatment of patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), or ER+/HER2-, estrogen receptor 1, or ESR1,-mutated advanced or metastatic breast cancer who have previously received endocrine-based therapy. The FDA has assigned a Prescription Drug User Fee Act, or PDUFA, action date of June 5, 2026, for vepdegestrant.

Arvinas, Inc. (NASDAQ:ARVN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for ARVN at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Arvinas Reports Strong Q4/FY2025 Results, Extends Cash Runway to H2 2028, and Repurchases $91.9M in Shares
  • Arvinas Announces CEO, President, and Board Chair Leadership Transition

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$262.6M
Net Income
-$80.8M
Diluted EPS
-$1.14
Op. Cash Flow
-$273.8M
Free Cash Flow
-$275.7M
Operating Income
-$118.5M
Cash & Equivalents
$142.9M
Total Debt
$600K
Debt / Equity
0.00×
Net Margin
-30.8%
Shares Outstanding
63.5M sh
Source: 10-K · filed 2026-02-24 · accession 0001628280-26-011226
$6.46
52-week range · as of 2026-11-03 $6.46 – $14.51
Market cap
$423.03M
Volume
1.1M (1.2× avg)
3-mo avg 935.4K
Live data · 2026-11-21 23:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ARVN - Filings & News (Page 2)

ARVN
Feb 24, 2026, 7:02 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.99
Real-time Price: $6.46 info
Change: -$5.53 (-46%) info
Market Cap: $423.033M info
ARVN
Feb 12, 2026, 7:06 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $13.12
Real-time Price: $6.46 info
Change: -$6.66 (-51%) info
Market Cap: $423.033M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets